Medicare AdvantageCoverageHigh impact
MA08.073v, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jul 2, 2026
Summary
Medicare Advantage policy MA08.073v establishes updated coverage and clinical guidelines for intravitreal injections of VEGF antagonists, VEGF biosimilars, and combination VEGF/Ang-2 inhibitors effective July 1, 2026. The billing team must review the full policy text to identify specific prior authorization requirements, covered medications, dosing limits, and any billing code changes that may affect claim submission and reimbursement for these retinal therapies.
Action Required
By June 15, 2026: Billing team must obtain and review the complete policy text at the provided URL to extract: (1) specific HCPCS codes for covered VEGF antagonists, biosimilars, and combination agents; (2) prior authorization requirements and submission processes; (3) any frequency or dosing limitations; (4) member cost-sharing details. Update billing software rules, prior auth workflows, and claim submission guidelines accordingly. Notify ophthalmology providers of any changes to coverage or authorization requirements. On July 1, 2026, begin enforcing new guidelines for all Medicare Advantage claims involving intravitreal VEGF-related injections. Claims submitted without proper prior authorization or using non-covered medications will be denied.